Skip Nav Destination
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Impact Factor
38.272
Featured Articles
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
AACR Project GENIE: 100,000 cases and beyond
Trevor J. Pugh, et al.
Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence
Simon Linder, Marlous Hoogstraat, et al.
Noted This Week
Daiichi Sankyo announced that the FDA granted accelerated approval to trastuzumab deruxtecan (Enhertu) to treat adults with inoperable or metastatic non–small cell lung cancer (NSCLC) whose tumors have HER2 mutations and who have already received a systemic therapy. The decision was based on the DESTINY-Lung02 trial, in which the confirmed overall response rate (ORR) was 58% and the median duration of response (DOR) was 8.7 months among 52 patients. The agency also approved Life Technologies' Oncomine Dx Target Test and Guardant Health's Guardant360 CDx as companion diagnostics.
Trending - Altmetric
Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer
Last mentioned on Wednesday August 17 2022
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer
Last mentioned on Wednesday August 17 2022
Tuning the Antigen Density Requirement for CAR T-cell Activity
Last mentioned on Wednesday August 10 2022
Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice
Last mentioned on Monday August 15 2022
In This Issue
Last mentioned on Tuesday August 16 2022
Advertisement